FUS, a protein tied to neurodegeneration, normally mends DNA breaks, according to a paper in Nature Neuroscience.
It's not just for neurodevelopment anymore. Death receptor 6—known for pruning axons—also trims unused connections in adulthood, hinting at a function in Alzheimer's.
Proposed preclinical stages for Alzheimer’s disease predict well who is most likely to progress to Alzheimer’s dementia.
A new RNA interference therapy for amyotrophic lateral sclerosis has some success in mice and monkeys.
In the first study of its kind, researchers found a surprisingly low incidence of Lewy body dementias in a U.S. population.
An inhibitor of a cellular stress response prevents neurodegeneration in mice infected with prion protein, and might have potential in other neurodegenerative diseases.
Clinical trials could prove the value of amyloid scans to health insurers.
The receptor tyrosine kinase ErbB4 could be the latest gene for amyotrophic lateral sclerosis.
A cancer drug-turned-Alzheimer’s prospect now appears to have potential against a third disease, reportedly protecting animal models from Parkinson’s damage.
Silencing aberrant C9ORF72 mRNA helps normalize pathology in neurons, suggesting the transcripts are toxic to the cells.
Among cognitively healthy older adults, the rate of change in cerebrospinal fluid biomarkers helps predict who will develop Alzheimer’s disease.
Screens of yeast and human-derived neurons uncover reasons for α-synuclein toxicity and potential ways to prevent it.
Deep brain stimulation restores walking and swimming abilities in rats with spinal injuries, so long as a few nerve fibers remain intact.
A meta-analysis of four large genome-wide association studies turned up 11 new risk genes for Alzheimer’s disease.
More evidence that an antisense RNA strategy might work for certain types of ALS and FTD.